<SEC-DOCUMENT>0001213900-19-001347.txt : 20190129
<SEC-HEADER>0001213900-19-001347.hdr.sgml : 20190129
<ACCEPTANCE-DATETIME>20190129115503
ACCESSION NUMBER:		0001213900-19-001347
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190129
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190129
DATE AS OF CHANGE:		20190129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		19547747

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k012919_optimizerxcorp.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>WASHINGTON, D.C. 20549<BR> </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>FORM 8-K</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B><BR>
<BR>
Date of Report (Date of earliest event reported): January 29, 2019<BR>
<BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">Nevada</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">000-53605</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">26-1265381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 66%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">400 Water Street, Suite 200, Rochester,
    MI</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">48307</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Registrant&rsquo;s telephone number, including area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">___________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
        last report)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT> &nbsp; &nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT> &nbsp; &nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT> &nbsp; &nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 29, 2019, we issued a press release announcing our partnership
with IllumiCare. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<TD STYLE="width: 20pt; text-align: left">99.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><A HREF="f8k012919ex99-1_optimizerx.htm">Press release, dated January 29, 2019</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 25%"><B>OptimizeRx Corporation</B></TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Douglas Baker</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Douglas Baker</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: January 29, 2019</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><BR> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k012919ex99-1_optimizerx.htm
<DESCRIPTION>PRESS RELEASE, DATED JANUARY 29, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white"><B>OptimizeRx
Announces New Partnership with Health IT Pioneer lllumiCare</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Partnership to open lines of communication
between pharma, providers and patients, supporting financial, clinical and drug education</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black; background-color: white"><B>ROCHESTER,
Mich., </B></FONT><B><FONT STYLE="color: Black">(January 29, 2019) &mdash;</FONT></B><FONT STYLE="color: Black"> <FONT STYLE="background-color: white"><U>OptimizeRx
Corp.</U> (</FONT>NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, announced a new
partnership with <U>IllumiCare</U>, a pioneer in point-of-care healthcare information technology that saves hospitals millions
annually. IllumiCare's Smart Ribbon&reg; platform will feature a new app from OptimizeRx, the RxSavings App, to present drug savings
opportunities&mdash;such as co-pay offers and vouchers&mdash;that providers and the clinical care team can distribute to the patient
directly at the point-of-care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&ldquo;At OptimizeRx, our singular focus
is to improve the lines of communication between pharma, providers and patients,&rdquo; said Miriam Paramore, president of OptimizeRx.
&ldquo;By bringing these stakeholders together, we can create a seamless continuum that impacts the healthcare industry greatly.
Our partnership with IllumiCare is an example of our long-standing commitment to bringing financial conversations to the forefront,
which not only helps affordability and adherence but improves overall outcomes as well.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">According to a recent report from three
major hospital and pharmacist groups, rising drug prices and drug shortages have impacted hospital budgets, with spending increasing
nearly 20 percent in three years. One such consequence of higher drug prices is forcing hospital staff to spend time searching
for substitute treatments, which can delay patient procedures and other services. The report noted that alternatives are often
also more expensive than usual care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&ldquo;Our collaboration with OptimizeRx
will enable providers to be better stewards of healthcare spending,&rdquo; said G.T. LaBorde, CEO of IllumiCare. &ldquo;Our Smart
Ribbon technology, accessible within the provider&rsquo;s workflow in the electronic health record (EHR), will give providers
easy access to render coupons, savings opportunities or alternate drug choices to best support the patient.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><FONT STYLE="color: Black">The
RxSavings App launch is set for Q2 of 2019. IllumiCare is EHR-agnostic and has integrations with Epic, Cerner, Allscripts, Meditech
and others. Known for providing cost and risk data to physicians directly at the point-of-care, the Smart Ribbon is customizable
to every hospital&rsquo;s needs. It displays a variety of apps based on context and user that illuminate opportunities to reduce
overutilization and enable providers to be better stewards of hospital and patient resources. The technology is live across more
than 120 hospitals in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">For more information on the partnership,
visit <U>www.optimizerx.com</U> or <U>www.illumicare.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>About IllumiCare</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Founded in 2014 in Birmingham, Ala.
by a visionary physician and team of hospital IT experts, IllumiCare is dedicated to helping clinicians become better stewards
of system and patient resources. Its Smart Ribbon<SUP>&reg;</SUP> platform brings clinicians critical, patient-specific data in
a focused view for expedited clinical decision making at the point of care, without disrupting clinical workflow. Hospitals around
the country are seeing the benefits of decreasing harmful overutilization: Immediately after go-live, providers drop their spend
per admission by $170. To learn more, visit <U>www.illumicare.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>About OptimizeRx</B><BR>
OptimizeRx&reg; (NASDAQ: OPRX) is one of the nation&rsquo;s leading providers of digital health messaging via electronic health
records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company&rsquo;s
cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization,
education, and critical clinical information. The company&rsquo;s network is comprised of leading EHR platforms like Allscripts,
Amazing Charts and Quest, and provides more than half of the ambulatory patient market with access to these benefits within their
workflow at the point-of-care. For more information, follow the company on&nbsp;<U>Twitter</U>,&nbsp;<U>LinkedIn</U>&nbsp;or visit&nbsp;<U>www.optimizerx.com</U>.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Important Cautions Regarding Forward
Looking Statements</B><BR>
Certain information contained in this press release includes &ldquo;forward-looking statements&rdquo; within the meaning of The
Private Securities Litigation Reform Act of 1995, including statements related to the proposed public offering, the filing of
the registration statement and potential market opportunity for our product candidates. We may, in some cases use terms such as
&ldquo;predicts,&rdquo; &ldquo;believes,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;might,&rdquo;
&ldquo;will,&rdquo; &ldquo;should&rdquo; or other words that convey uncertainty of the future events or outcomes to identify these
forward-looking statements. Our forward-looking statements are based on current expectations that involve risks, potential changes
in circumstances, assumptions and uncertainties. Any or all of the forward-looking statements may turn out to be wrong, or be
affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties as a result of various important
factors, including the uncertainties related to market conditions, our ability to satisfy the closing conditions of the offering,
the timing or occurrence of the closing, and the anticipated use of the proceeds of the offering, which could change as a result
of market conditions or for other reasons. For a further description of the risks and uncertainties that could cause actual results
to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, please
refer to our prospectus supplement filed with the Securities and Exchange Commission (SEC) on December 17, 2018 under the heading
&ldquo;Risk Factors&rdquo; and those documents incorporated by reference therein, which includes our Annual Report on Form 10-K
filed with the SEC on March 8, 2018. You are cautioned not to place undue reliance on these forward-looking statements, which
are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements
to reflect subsequent events or circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>OptimizeRx Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Doug Baker, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (248) 651-6568 x807</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black"><U>dbaker@optimizerx.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Media Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Nicole Brooks, Innsena Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">(Tel) 860-800-2344</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black"><U>nicolebrooks@innsena.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Investor Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Ron Both, CMA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (949) 432-7557</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black"><U>oprx@cma.team</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R /L# 2(  A$! Q$!_\0
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MV>"*2,,L;*$?S 3_ !<@ C&,'KGCV>N^IB(4)>SIQ6@K7/F_PS\4_$&@7/\
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M47TV>WFEN7M!($:)E0@R ?P[2WWNV:GZI*%6,6]'U"YS7P0_Y'2\_P"P>_\
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M# =/X/R[/1[V9/@D\$Y>5VTNX =G)PC!]H^@4@ >@KR9CKGC_P 3#$9EN9W
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MS9TLFU"GRL2C>3SC/&.?E&!TY/S=*WI/%%VO@VYUU],%NZD"".23<'4E5#]
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-'34445Z!04444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
